China Pharma Holdings, Inc.
CPHI NYSE
SEC CIK 1106644
Follow China Pharma
Weekly email: filings, results
Revenue, last quarter
$1.2M
+52.5% vs same quarter last year
Net income
−$1.9M
−191.9% vs same quarter last year
EPS, diluted
−$0.04
+76.5% vs same quarter last year
Operating cash flow
−$1.1M
−441.9% vs same quarter last year
Source: SEC XBRL filings · latest filing
- Revenue
- Net income
Show the numbers
| Year | Revenue | Net income |
|---|---|---|
| FY25 | $4.1M | −$3.2M |
| FY24 | $4.5M | −$4.7M |
| FY23 | $7M | −$3.1M |
| FY22 | $8.1M | −$4M |
| FY21 | $9.6M | −$3.4M |
| FY20 | $10.9M | −$2.9M |
| FY19 | $10.9M | −$20.7M |
| FY18 | $12.3M | −$10.8M |
| FY17 | $13.2M | −$19.3M |
| FY16 | $15.6M | −$9.2M |
| FY15 | $20.4M | −$15.4M |
| FY14 | $22.1M | −$39.6M |
| FY13 | $32.8M | −$20M |
| FY12 | $54.5M | $4.6M |
| FY11 | $81.2M | $19.3M |
- Gross margin
- Operating margin
- Net margin
Show the numbers
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY25 | −3.2% | −78.2% | −76.9% |
| FY24 | −43.8% | −101.3% | −104.6% |
| FY23 | −4% | −39.2% | −43.9% |
| FY22 | −6.1% | −43.8% | −49% |
| FY21 | 3.6% | −29.7% | −35.3% |
| FY20 | 18% | −23.7% | −26.4% |
| FY19 | 13.6% | −186.8% | −189.5% |
| FY18 | 16% | −84.7% | −87.2% |
| FY17 | 18.7% | −141.4% | −145.9% |
| FY16 | 20.7% | −52.4% | −59% |
| FY15 | 7.2% | −70.3% | −75.7% |
| FY14 | 12.1% | −175.1% | −178.7% |
| FY13 | −1.5% | −56.7% | −61% |
| FY12 | 25.8% | 10.8% | 8.5% |
| FY11 | 35.7% | 27.1% | 23.7% |
Show the numbers
| Year | Free cash flow |
|---|---|
| FY25 | $88.9K |
| FY24 | −$444.5K |
| FY23 | −$711.2K |
| FY22 | −$811.5K |
| FY21 | −$687.9K |
| FY20 | −$909.6K |
| FY19 | $472.3K |
| FY18 | $1.8M |
| FY17 | $704.7K |
| FY16 | $2.7M |
| FY15 | $2.7M |
| FY14 | $1M |
| FY13 | −$10.2M |
| FY12 | $3.5M |
| FY11 | $4.9M |
- China Pharma
- Healthcare median
Show the numbers
| Year | China Pharma | Healthcare median |
|---|---|---|
| FY25 | −76.9% | −30.6% |
| FY24 | −104.6% | −47% |
| FY23 | −43.9% | −58% |
| FY22 | −49% | −80.4% |
| FY21 | −35.3% | −71.9% |
| FY20 | −26.4% | −62.2% |
| FY19 | −189.5% | −46.3% |
| FY18 | −87.2% | −49.6% |
| FY17 | −145.9% | −45.9% |
| FY16 | −59% | −36% |
| FY15 | −75.7% | −38.4% |
| FY14 | −178.7% | −35.5% |
| FY13 | −61% | −37.1% |
| FY12 | 8.5% | −29.1% |
| FY11 | 23.7% | −27.9% |